Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 263 participants.
Also called NCT02653482
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 263 participants
- Sponsor
- Registry
-
NCT02653482
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02653482. Randomized; quadruple masking; primary purpose treatment. Start 2016-03-03 (actual); primary completion 2019-06-28 (actual). Results posted on 2021-12-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
- Acronym
- DEFINE-HF
- Condition
- Chronic Heart Failure With Reduced Systolic Function
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Dapagliflozin matching placebo
- Lead sponsor
- Saint Luke's Health System
Record details
- Record id
cardio:ct-nct02653482- Content hash
362ce8a2ad4eddacfed09da8867169606f7175cbce3138fb877cdf5d63342b78